SANTA ANA, CA - (NewMediaWire) - December 28, 2015 - ADVANTIS CORPORATION (OTC PINK: ADVT) has announced the finalization and execution of participating Southern California 7-Eleven and 76 Gas Station distribution deal.
On the dawn of signing its first exclusive distribution agreement with LipMedRX, LLC., Advantis Corp announced it has successfully negotiated, drafted, and executed an agreement with participating Southern California 7-Eleven and 76 Gas Station stores.
Advantis Corp's Vice President, Geoffrey Broderick, stated in a recent press conference, "First we have under our corporate belt what is the first ground breaking cold and flu preventive product in the lip balm industry; then we achieved the execution of a deal to have Advantis be the exclusive distributor, and now we have taken the ultimate step of successfully lining up 7-Eleven and 76 Gas Stations to officially launch LipMedRX in participating Southern California 7-Eleven and 76 Gas Station locations."
Advantis Director Woo Kim reiterated, "This great news reflects one of the many steps Advantis has been taking to help build shareholder value by timing the recent Advantis rebranding process to coincide with the imminent finalization of several agreements which will no doubt welcome Advantis to the big leagues." Broderick added, "This focus on shareholder value is starting to become apparent as we finally move from mere negotiation and contract to a 'brick and mortar' presence with a product that promises to bring great success in 2016 and beyond!"
LipMedRX is an innovative anti-germ lip balm protectant, for which studies have shown to be highly effective in killing those germs associated with cold and flu on the lips before they enter the mouth. According to a report released by LipMedRX, LLC, the Anti-Flu & Cold Lip Balm Protectant is the first ever lip balm that kills germs on the lips before they can enter the body. The product was designed to not only provide protection from germs but also be a moisturizing agent that keeps lips soft and smooth. According to Geoffrey Broderick, "This is the type of innovation that has the ability to sweep the market share of its product category, and the good news is that this is just one of several deals that we are working on... stay tuned; the best has yet to come."
ABOUT Advantis Corporation
Advantis Corporation (ADVT) focuses on the development of innovative products that supply the medical, research, and pharmaceutical industries. In addition, the company is establishing domestic and international partnerships with businesses that develop and sell proprietary consumer products and services. Product lines for consumer health care, music and entertainment sectors are in development.
Forward Looking Statements: This news release contains forward-looking statements made by ADVANTIS CORPORATION. All such statements included in this press release, other than statements of historical fact, are forward-looking statements. Although management believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Actual results may differ materially from those indicated by these statements. The following risk factors, among others, could cause actual results to differ materially from those described in any forward-looking statements. These risks and uncertainties include, but are not limited to, economic conditions, changes in the law or regulations, demand for products of the Company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward looking statements. Forward-looking statements are typically identified by the words: believe, expect, anticipate, intend, estimate, and similar expressions or which by their nature refer to future events. The Company is not entitled to rely on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 because it is not registered under either Act.